1072833-77-2
Product Name:
(R)-1-(2-(2,5-dichlorobenzamido)acetamido)-3-methylbutylboronic acid
Formula:
C14H19BCl2N2O4
Inquiry
COMPUTED DESCRIPTORS
| Molecular Weight | 361.0 g/mol |
|---|---|
| Hydrogen Bond Donor Count | 4 |
| Hydrogen Bond Acceptor Count | 4 |
| Rotatable Bond Count | 7 |
| Exact Mass | 360.0814926 g/mol |
| Monoisotopic Mass | 360.0814926 g/mol |
| Topological Polar Surface Area | 98.7 Ų |
| Heavy Atom Count | 23 |
| Formal Charge | 0 |
| Complexity | 412 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 1 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently-Bonded Unit Count | 1 |
| Compound Is Canonicalized | Yes |
PRODUCT INTRODUCTION
description
Ixazomib is a glycine derivative that is the amide obtained by formal condensation of the carboxy group of N-(2,5-dichlorobenzoyl)glycine with the amino group of [(1R)-1-amino-3-methylbutyl]boronic acid. The active metabolite of ixazomib citrate, it is used in combination therapy for treatment of multiple myeloma. It has a role as an apoptosis inducer, an orphan drug, a proteasome inhibitor, a drug metabolite and an antineoplastic agent. It is a member of benzamides, a dichlorobenzene, a glycine derivative and a member of boronic acids.